4//SEC Filing
Boulding Mark Elliott 4
Accession 0001578852-26-000002
CIK 0001070081other
Filed
Jan 5, 7:00 PM ET
Accepted
Jan 6, 5:20 PM ET
Size
17.4 KB
Accession
0001578852-26-000002
Insider Transaction Report
Form 4
Boulding Mark Elliott
EXEC. VP AND CLO
Transactions
- Award
Common Stock
2026-01-02+17,000→ 120,901 total - Exercise/Conversion
Common Stock
2026-01-05$39.42/sh+2,266$89,326→ 123,167 total - Sale
Common Stock
2026-01-05$74.92/sh−1,123$84,135→ 122,044 total - Sale
Common Stock
2026-01-05$76.10/sh−1,035$78,764→ 121,009 total - Sale
Common Stock
2026-01-05$76.79/sh−108$8,293→ 120,901 total - Award
Stock Option (Right to Buy)
2026-01-02+42,500→ 42,500 totalExercise: $76.74Exp: 2036-01-01→ Common Stock (42,500 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2026-01-05−2,266→ 9,063 totalExercise: $39.42Exp: 2033-01-04→ Common Stock (2,266 underlying)
Footnotes (7)
- [F1]Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027.
- [F2]This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.
- [F3]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $74.55 to $75.27 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F4]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.58 to $76.42 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F5]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.75 to $76.81 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F6]This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027.
- [F7]This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
Documents
Issuer
PTC THERAPEUTICS, INC.
CIK 0001070081
Entity typeother
Related Parties
1- filerCIK 0001578852
Filing Metadata
- Form type
- 4
- Filed
- Jan 5, 7:00 PM ET
- Accepted
- Jan 6, 5:20 PM ET
- Size
- 17.4 KB